GEMCITABINE

Gemcitabine

Composition: each 10 ml vial contains:

active substance: gemcitabine (as gemcitabine hydrochloride) – 200 mg and 1000 mg.

Therapeutic indications

Treatment of localised or metastatic bladder cancer in combination with cisplatin.

Treatment of localised or metastatic pancreatic adenocarcinoma.

First-line therapy of localised or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin. Gemcitabine monotherapy is possible in elderly patients or patients with physical function 2.

Treatment of localised or metastatic epithelial ovarian cancer in combination with carboplatin in relapse patients after at least 6 months of delaying time to relapse after the end of the first line of platinum-based therapy.

Complex treatment with paclitaxel of localised unresectable or metastatic breast cancer in relapse patients after adjuvant/non-adjuvant chemotherapy. The primary therapy shall include anthracycline in absence of contraindications.

	АТС code
	L01BC05
	Pharmaceutical form
	lyophilized powder for solution for infusion 200 mg, 1000 mg
	Storage conditions
	Store in protected from moisture and light place at temperature below 25°C.